ECSP055528A - Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco - Google Patents

Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco

Info

Publication number
ECSP055528A
ECSP055528A EC2005005528A ECSP055528A ECSP055528A EC SP055528 A ECSP055528 A EC SP055528A EC 2005005528 A EC2005005528 A EC 2005005528A EC SP055528 A ECSP055528 A EC SP055528A EC SP055528 A ECSP055528 A EC SP055528A
Authority
EC
Ecuador
Prior art keywords
uniform distribution
farmaco
power
pharmaceutical composition
active ingredient
Prior art date
Application number
EC2005005528A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055528A publication Critical patent/ECSP055528A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones farmacéuticas que poseen una distribución y potencia de fármaco uniforme, que utilizan lasofoxifeno como ingrediente activo, y que contienen un dióxido de silicio para reducir la pérdida de ingrediente activo durante el proceso de fabricación, y métodos para fabricar estas composiciones.
EC2005005528A 2002-07-10 2005-01-10 Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco ECSP055528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10

Publications (1)

Publication Number Publication Date
ECSP055528A true ECSP055528A (es) 2005-03-10

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005528A ECSP055528A (es) 2002-07-10 2005-01-10 Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco

Country Status (35)

Country Link
US (2) US20040057992A1 (es)
EP (1) EP1534248B1 (es)
JP (2) JP4446446B2 (es)
KR (1) KR100782693B1 (es)
CN (1) CN100344278C (es)
AP (1) AP2005003201A0 (es)
AR (1) AR040434A1 (es)
AT (1) ATE550017T1 (es)
AU (1) AU2003247017B2 (es)
BR (1) BR0312563A (es)
CA (1) CA2489407C (es)
CY (1) CY1112892T1 (es)
DK (1) DK1534248T3 (es)
EA (1) EA007268B1 (es)
EC (1) ECSP055528A (es)
ES (1) ES2395123T3 (es)
HN (1) HN2003000206A (es)
HR (1) HRP20041196A2 (es)
IL (2) IL165746A0 (es)
IS (1) IS7594A (es)
MA (1) MA27318A1 (es)
MX (1) MXPA05000394A (es)
NO (1) NO20050018L (es)
NZ (1) NZ537278A (es)
OA (1) OA12883A (es)
PA (1) PA8576201A1 (es)
PE (1) PE20040104A1 (es)
PL (1) PL374913A1 (es)
PT (1) PT1534248E (es)
SI (1) SI1534248T1 (es)
TN (1) TNSN05006A1 (es)
TW (1) TW200406222A (es)
UY (1) UY27886A1 (es)
WO (1) WO2004006895A1 (es)
ZA (1) ZA200410196B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
CN101198319B (zh) * 2005-04-26 2012-08-01 大日本住友制药株式会社 含有双胍化合物的颗粒制剂
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
CA2835910C (en) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Improved vitamin d content uniformity in pharmaceutical dosage forms
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
WO2009048557A1 (en) * 2007-10-10 2009-04-16 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20090274757A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
SI2451445T1 (sl) * 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
WO2013059146A1 (en) * 2011-10-17 2013-04-25 Lexicon Pharmaceuticals, Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
JP5818219B2 (ja) 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
MX382609B (es) * 2016-07-25 2025-03-13 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AP2003002900A0 (en) * 2001-05-01 2003-12-31 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
OA12883A (en) 2006-09-15
CA2489407C (en) 2009-01-27
EA200401583A1 (ru) 2005-06-30
US7553500B2 (en) 2009-06-30
CN1668285A (zh) 2005-09-14
TNSN05006A1 (fr) 2007-05-14
AR040434A1 (es) 2005-04-06
NZ537278A (en) 2007-07-27
JP2005535671A (ja) 2005-11-24
ZA200410196B (en) 2006-07-26
MXPA05000394A (es) 2005-03-23
UY27886A1 (es) 2004-02-27
CA2489407A1 (en) 2004-01-22
EP1534248A1 (en) 2005-06-01
PL374913A1 (en) 2005-11-14
AU2003247017A1 (en) 2004-02-02
IS7594A (is) 2004-12-13
TW200406222A (en) 2004-05-01
KR20050017102A (ko) 2005-02-21
US20040057992A1 (en) 2004-03-25
IL165746A0 (en) 2006-01-15
PT1534248E (pt) 2012-05-25
PE20040104A1 (es) 2004-02-27
EP1534248B1 (en) 2012-03-21
EA007268B1 (ru) 2006-08-25
HN2003000206A (es) 2004-07-27
NO20050018L (no) 2005-01-12
BR0312563A (pt) 2005-04-19
CY1112892T1 (el) 2016-04-13
MA27318A1 (fr) 2005-05-02
AP2005003201A0 (en) 2005-03-31
SI1534248T1 (sl) 2012-07-31
ES2395123T3 (es) 2013-02-08
AU2003247017B2 (en) 2008-03-06
CN100344278C (zh) 2007-10-24
JP2007031451A (ja) 2007-02-08
DK1534248T3 (da) 2012-06-25
IL165746A (en) 2008-12-29
HRP20041196A2 (en) 2005-04-30
WO2004006895A1 (en) 2004-01-22
KR100782693B1 (ko) 2007-12-07
PA8576201A1 (es) 2004-05-26
JP4446446B2 (ja) 2010-04-07
US20070110800A1 (en) 2007-05-17
HK1077747A1 (en) 2006-02-24
ATE550017T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
DK1487461T3 (da) Fremgangsmåder til anvendelse af og præparater omfattende immunomodulatoriske forbindelser til behandling og håndtering af myelodysplastiske syndromer
GT199900203A (es) Composiciones de celecoxib.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ECSP055726A (es) Composición farmacéutica estabilizada que contiene excipientes básicos
TW200716628A (en) Novel compounds
SE9900961D0 (sv) Novel compounds
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
AR033293A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
DOP2003000655A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose